Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Report: Merck’s Uprifosbuvir Faces Fight to Be Profitable

By GlobalData Plc | March 14, 2017

Merck’s uprifosbuvir faces fight to be profitable in declining hepatitis C market, says GlobalData.

Due to various setbacks and adverse market dynamics, Merck & Co.’s newest direct-acting antiviral (DAA) for hepatitis C, uprifosbuvir, will represent only a minor player in the hepatitis C market by 2025, according to research and consulting firm GlobalData.

In a recent Form 8-K filing submitted to the U.S. Securities and Exchange Commission, Merck announced the revaluation of its newest NS5B inhibitor uprifosbuvir (formerly MK-3682) at $240 million, resulting in a pre-tax impairment charge of $2.9 billion. Merck originally acquired the drug through its 2014 purchase of Idenix for $3.85 billion.

As explored in GlobalData’s most recent hepatitis C report, the market is set to see a decline from $21.7 billion in 2015 to $17.5 billion by 2025 due to recent advances in hepatitis C treatment. Indeed, the remarkably high cure rate of DAAs results in a fast and substantial reduction in the number of diagnosed patients requiring treatment. This fact, combined with uprifosbuvir’s mixed performance in a crucial eight-week therapy regimen for treatment-naïve hepatitis C virus (HCV)-infected patients, means the drug will face limitations on entering the market.

Mirco Junker, Ph.D., Healthcare Analyst for GlobalData, explains: “Currently, HCV treatment access is limited, due to its high cost. If prices drop below a country-specific level, insurance companies — and in particular governmental programs — will have a significant incentive to treat as many patients as quickly as possible, consequently eliminating the need for DAAs even prior to major drug patent expirations.

“It is not yet clear whether DAA combinations with uprifosbuvir will enter Phase III studies. Should the market dynamics develop as expected by GlobalData, the development of uprifosbuvir would still be profitable, despite only covering a small portion of the market share. However, in the event of DAA prices declining further and governments initiating aggressive treatment coverage, the overall market size could shrink quickly below the profitability level for uprifosbuvir.”

(Source: GlobalData)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE